Abstract | PURPOSE: There are few treatment options for patients with metastasized or inoperable endocrine gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the response is usually less than 1 year. Here, we present the results of treatment with a radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate). PATIENTS AND METHODS: RESULTS: One patient developed renal insufficiency, and another patient developed hepatorenal syndrome. Creatinine clearance did not change significantly in the other patients. WHO hematologic toxicity grade 3 or 4 occurred after less than 2% of the administrations. We observed complete remission in three patients (2%), partial remission in 32 patients (26%), minor response ( tumor diameter decrease of 25% to 50%) in 24 patients (19%), stable disease (SD) in 44 patients (35%), and progressive disease (PD) in 22 patients (18%). Higher remission rates were positively correlated with high uptake on pretherapy somatostatin receptor imaging and a limited number of liver metastases, whereas PD was significantly more frequent in patients with a low performance score and extensive disease. Median time to progression in 103 patients who either had SD or tumor regression was more than 36 months. CONCLUSION: Treatment with 177Lu-octreotate results in tumor remission in a high percentage of patients with GEP tumors. Serious side effects are rare. The median time to progression compares favorably with chemotherapy. Results are better in patients with a limited tumor load. Therefore, early treatment, even in patients who have no PD, may be better.
|
Authors | Dik J Kwekkeboom, Jaap J Teunissen, Willem H Bakker, Peter P Kooij, Wouter W de Herder, Richard A Feelders, Casper H van Eijck, Jan-Paul Esser, Boen L Kam, Eric P Krenning |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 23
Issue 12
Pg. 2754-62
(Apr 20 2005)
ISSN: 0732-183X [Print] United States |
PMID | 15837990
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Organometallic Compounds
- Receptors, Somatostatin
- lutetium Lu 177 dotatate
- Octreotide
|
Topics |
- Adenoma, Islet Cell
(drug therapy, pathology)
- Adult
- Aged
- Aged, 80 and over
- Carcinoid Tumor
(drug therapy, pathology)
- Disease Progression
- Endocrine Gland Neoplasms
(drug therapy, pathology)
- Female
- Humans
- Liver Neoplasms
(drug therapy, secondary)
- Male
- Middle Aged
- Octreotide
(analogs & derivatives)
- Organometallic Compounds
(adverse effects, pharmacokinetics, therapeutic use)
- Pancreatic Neoplasms
(drug therapy, pathology)
- Receptors, Somatostatin
- Treatment Outcome
|